Earnings ·
Amphastar reports Q3 net income of $37.8M and authorizes $50M share buyback increase
AMPHAmphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals reported third-quarter 2026 GAAP net income of $37.8 million, or $0.87 per diluted share, compared to $17.4 million in the prior year period. Net revenues rose 8% to $207.6 million, driven by strong sales of BAQSIMI and Primatene MIST. Adjusted non-GAAP net income was $49.3 million, or $1.14 per share. The company also announced that its Board authorized a $50 million increase to its existing share repurchase program on November 4, 2026. Amphastar is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.